Point Mutation Cell Line

Over 75,000 human diseases are associated with genetic variants, with single-nucleotide mutations being the most prevalent. Constructing gene point mutation cell lines holds significant potential in the detection, study, and treatment of genetic disorders and cancers caused by single-nucleotide changes. The primary strategy for introducing point mutations is CRISPR/Cas9 technology, where gRNA guides the Cas9 nuclease to the target locus, generating DNA double-strand breaks (DSBs) that trigger cellular repair pathways. Typically, homology-directed repair (HDR) introduces the desired mutation. However, this approach presents challenges, including low editing efficiency, low homozygosity rates, and the risk of random insertions or deletions (indels).

Service Details

Cell Type Various cell types including tumor cells, epithelial cells, and stem cells.Click to view the full list of cell lines
Service Types Model construction / Efficiency validation for therapeutic applications / DNA sourcing
Delivery Standard Gene point mutation monoclonal cell line ≥ 1 clone (2 vials per clone, 1×10^6 cells per vial)
Timeline/Pricing   Consult online for details
EDITGENE’s newly developed Bingo™ platform is an advanced version of the Prime Editing (PE) system, the most efficient and safest tool for precise gene point mutation. This platform provides tailored services for generating highly accurate and efficient gene point mutation cell lines. Leveraging over a decade of expertise in gene editing, EDITGENE has refined its methods through thousands of gene editing CRO projects, achieving success rates that significantly exceed those of traditional gene editing systems.
 
Prime Editing Mechanism: The core mechanism of Prime Editing involves the use of a specialized guide RNA known as pegRNA. This RNA not only directs the system to the target sequence but also encodes the desired base modification. When paired with the PEmax gene-editing enzyme (Cas9n-RT), the system precisely targets the genomic site, allowing for the insertion of the desired DNA sequence, resulting in highly accurate single-nucleotide substitutions or small-scale insertions and deletions.

Service Advantages

Efficient Editing System
Superior editing efficiency and homozygosity rates compared to HDR-based methods.
Optimized pegRNA Design
Proprietary algorithms ensure precise and reliable pegRNA design.
Enhanced Cas9n-RT Enzyme
Optimized Cas9n-RT enzyme with improved activity and stability for superior editing outcomes.
Advanced Transfection System
Exclusive transfection system with 10x efficiency over traditional methods.
Streamlined Monoclonal Screening
3D printing technology enables efficient isolation of positive clones
Experienced Team
Expert team with over 1000 gene editing projects and experience across 300+ cell types.

Service Types

Tailored point mutation strategy design based on client requirements and comprehensive genetic analysis.
1 Construction of point mutation cell line models
2 Gene knockout with no off-target risk through premature stop codon introduction
3 pegRNA efficiency validation for therapeutic applications
4 Biological source material for standard DNA in in vitro diagnostics (IVD)

Service Workflow

Case Study

EDITGENE provides tailored point mutation strategies, integrating target gene and cell-specific characteristics according to client specifications.
 
● Successfully generated A gene point mutation in Ishikawa cells utilizing Prime Editing technology
 
1. Point Mutation Strategy
The p.D200A mutation of gene A is located in exon 3, corresponding to the nucleotide change c.A599C. Design the pegRNA and Nick sgRNA at the region highlighted in red.
 
 
Diagram of the gene A editing site
 
 
 
Functional diagram of pegRNA and Nick SgRNA
 
 
2. Polyclonal Editing Efficiency
During the polyclonal expansion phase, genome editing efficiency was assessed, with results demonstrating an approximate efficiency of 60%.
 
 
Editing efficiency assays
 
 
3. Monoclonal Sequencing Validation
PCR amplification and subsequent sequencing analysis verified that the monoclonal clone successfully harbors the precise c.A599C nucleotide substitution.
 
 
Monoclonalsequencing peak Graph

Advantage and Characteristic

Optimazied Strategy
We have create a unique sgRNA Design Logic
Optimazied Strategy
We have create a unique sgRNA Design Logic
Optimazied Strategy
We have create a unique sgRNA Design Logic
Optimazied Strategy
We have create a unique sgRNA Design Logic

Genetic Reference Book

PE7 editing system developed based on LA as a prime editing enhancer
Article Title: Improving prime editing with an endogenous small RNA-binding protein

Many studies focus on enhancing the performance of the Prime editor to increase its editing efficiency; however, the understanding of how Prime editing operates within cellular environments and how interactions with the cellular environment affect editing outcomes remains limited. Researchers sought to identify other cellular determinants affecting Prime editor efficiency and conducted related studies.
Through genome-scale CRISPR interference (CRISPRi) screening, researchers discovered a key Prime editing enhancer—La, a small RNA-binding exoribonuclease protector protein. The La protein binds to pegRNAs’ 3' polyU sequence through its N-terminal domain, enhancing Prime editing. This effect of the La protein is effective for different editing types (substitutions, insertions, deletions) and various cell types. Based on this finding, researchers developed a new Prime editor protein (PE7), in which the La RNA-binding N-terminal domain is fused to the PEmax editor. PE7 significantly improves Prime editing efficiency with expressed pegRNAs, engineered pegRNAs (epegRNAs), and synthetic pegRNAs optimized for La binding.

Article Title: Structural basis for pegRNA-guided reverse transcription by a prime editor

The molecular mechanism of how the Prime editor recognizes pegRNA and interacts with target DNA remains unclear, limiting the understanding and optimization of the prime editing process. To address this, researchers determined the cryo-electron microscopy (cryo-EM) structure of the Prime editor in various states, providing a structural framework for understanding this innovative genome engineering system.
Using cryo-EM technology, researchers analyzed the Prime editor complex’s structure in different states, including pre-initiation, initiation, extension, and termination, successfully obtaining high-resolution structures that reveal dynamic changes in the reverse transcription guidance process. Based on structural information, researchers designed pegRNA and Prime editor variants, truncating and fusing M-MLV RT to create a smaller Prime editor variant (PECO-Mini) that maintained editing efficiency while increasing AAV vector titers and prime editing efficiency. Activity testing results showed that the engineered Prime editor variant has comparable activity to the original Prime editor in vitro. This study reveals the structural characteristics of the Prime editor complex in various working states, providing key information for understanding its molecular mechanism.

Article Title: A truncated reverse transcriptase enhances prime editing by split AAV vectors

Prime editing is a novel CRISPR-based genome-editing technology that does not require double-strand DNA breaks or exogenous donor template DNA, showing great potential in biomedical research and gene therapy. Despite its versatility and precision, prime editing efficiency varies across different editing types, target sites, and cell types. Therefore, to expand its applications, there is a need to improve prime editing efficiency.
Researchers screened 11 different RT variants, optimized with GenScript algorithm for human codons, which increased PE protein expression levels by 1.4-fold. By deleting the RNase H domain and further shortening the RT sequence, they created multiple truncated PECO variants, reducing the Prime editor length by 621 bp without compromising editing efficiency. To enable efficient dual-AAV delivery of PE, the team constructed a split PE system based on different Cas9 cleavage sites and inteins, identifying cleavage sites Rma 573-574 and 674-675. When these sites were paired with Rma intein, they significantly increased AAV vector titers and Prime editor efficiency. Through engineering and optimization, researchers successfully enhanced Prime editing efficiency and resolved AAV size constraints, providing a more efficient tool for future gene therapy and biomedical research.

Article Title: Structural basis for pegRNA-guided reverse transcription by a prime editor

This article elucidates the structural basis of pegRNA-guided reverse transcription in prime editing technology. High-resolution structural analysis revealed the three-dimensional conformation of key proteins in the Prime Editor, including Cas9 and reverse transcriptase, and their interaction with pegRNA. It details how pegRNA guides the Prime Editor to recognize specific DNA sequences and perform reverse transcription, inserting a predetermined gene sequence into the target site. The study also discusses the roles of key amino acid residues in pegRNA binding and reverse transcription, providing insight into the precise mechanisms of these molecular interactions. This finding not only deepens our understanding of the Prime Editing mechanism but also offers valuable structural information for optimizing and improving this technology, advancing its application in gene therapy and other fields.

Article Title: Ex vivo prime editing of patient haematopoietic stem cells rescues sickle-cell disease phenotypes after engraftment in mice

Sickle-cell disease (SCD) is an autosomal recessive genetic disorder caused by an A·T to T·A point mutation in the β-globin gene (HBB). Currently, the only FDA-approved cure for SCD is allogeneic hematopoietic stem cell transplantation; however, most patients lack ideal donors, and this procedure can lead to severe toxicity. Correcting a patient’s own hematopoietic stem cells (HSCs) can bypass immune complications and eliminate the need for matched donors. Clinical trials are ongoing to correct the SCD mutation using Cas9 nuclease-initiated homology-directed repair (HDR) and adeno-associated virus type 6 (AAV6)-delivered DNA templates.
In this article, researchers applied an optimized prime editing system to correct HSPCs from SCD patients ex vivo. By electroporating PEmax mRNA along with synthetic epegRNA and nicking sgRNA, the SCD allele (HBBS) was successfully corrected back to the wild-type (HBBA), with correction rates between 15% and 41%. Subsequently, edited HSPCs were transplanted into immunodeficient mice, and 7 weeks later, edited HSPCs maintained HBBA levels in the bone marrow, with engraftment rates, hematopoietic differentiation, and lineage maturation similar to unedited healthy donor HSPCs. Therapeutic evaluation revealed that, post-transplant, 42% of red blood cell precursors and reticulocytes expressed HBBA, exceeding the predicted therapeutic benefit level. Gene-specific analyses also confirmed high DNA specificity of the prime editing system. The study demonstrates the potential of prime editing in SCD treatment, showing its effectiveness in improving therapeutic outcomes while reducing off-target editing risks.

Article Title: Generation of Human Isogenic Induced Pluripotent Stem Cell Lines with CRISPR Prime Editing

With advancements in human molecular genetics and genomics, thousands of gene loci associated with common disease risks have been identified, often containing multiple candidate variants. However, most disease-associated variants are non-coding, making it challenging to elucidate the molecular mechanisms underlying these variants. The development of CRISPR technology provides a more precise approach for targeted genome editing, particularly prime editing, which can mediate nearly any single-nucleotide substitution. Consequently, many researchers hope to apply prime editing to study the functional relevance of specific gene variants in pluripotent stem cells, enabling the generation of isogenic cell lines to control genetic background while assessing the dose effect of causal alleles.
In this article, researchers developed an efficient CRISPR prime editing technology to generate cell lines carrying heterozygous or homozygous alleles in induced pluripotent stem cells (iPSCs) and optimized the prime editing technique. Six single-nucleotide variants (SNVs) associated with Type 2 Diabetes (T2D) risk were selected for editing, and iPSCs derived from human donors with different genetic backgrounds were edited at each site. The researchers successfully generated 27 edited iPSC clones covering 6 SNVs associated with T2D or congenital hyperinsulinemia (CHI) and found that prime editing was more efficient in iPSCs than in HEK293T cells. Overall, this study demonstrates the potential of prime editing for generating iPSCs with specific genetic backgrounds, providing a powerful tool to study the effects of specific genetic variants on disease.

FAQ

What is Prime Editing?
Prime Editing is a novel gene editing technology that enables precise gene editing without introducing double-strand DNA breaks. It has two core components: pegRNA and the PEmax gene-editing enzyme (Cas9n-RT). PegRNA not only targets the desired sequence but also contains the base modification information. In the editing system, pegRNA guides PEmax to the designated edit site, nicks the DNA single strand, and reverse transcribes the sequence within the pegRNA to modify, inserting it into the target genome location, thereby achieving precise single-base substitutions or small insertions and deletions
EDITGENE’s Bingo™ Prime Editing 7 (PE7) platform is built upon over ten years of gene editing experience, with optimization and advancements derived from thousands of gene editing CRO projects, achieving significantly higher success rates than traditional site-specific mutation systems. The Bingo™ Prime platform utilizes highly efficient reverse transcriptase and precise guide RNA design, ensuring each point mutation reaches the desired outcome.
EDITGENE’s newly upgraded seventh-generation Bingo™ Prime Editing (PE7) platform optimizes editing protein and RNA editing activity. Compared to the fifth-generation PE technology, point mutation success rates and gene editing efficiency have significantly improved, with one-on-one support from PhDs from globally renowned institutions.
Traditional CRISPR/Cas9 technology achieves gene editing by introducing double-strand breaks at the target DNA site and then using the cell’s homologous recombination repair mechanism. This approach carries multiple risks, such as lower editing efficiency, reduced homozygous mutation rates, and random insertions or deletions. Prime Editing, however, does not require double-strand breaks. With its Cas9n-RT editing enzyme system and pegRNA, Prime Editing achieves more accurate and safer gene editing with reduced off-target effects.
EDGENE

Contact US

web logo
Kathy
Tel: info@editxor.com
Tel: 833-2263234
(USA Toll-free)
Tel: +1-224-345-1927
(USA)
Tel: +86-19120353110
(Intl)
在线客服